MedTrace Logo

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

NCT04229355 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-02-09

No results posted yet for this study

Summary

Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment. In recent years, lenvatinib and anti-PD-1 have exhibited potential therapeutic effects for advanced HCC. And sorafenib is the standard drug for advanced HCC. Combining targeted drugs or immunotherapies with DEB-TACE may provide synergistic effects and facilitate the development of personalized medicine. Therefore, this prospective study aims to investigate the safety and efficacy of DEB-TACE plus sorafenib or lenvatinib or PD-1 Inhibitor for unresectable HCC.

Conditions

Interventions

DRUG

DEB-TACE plus Sorafenib

Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)

DRUG

DEB-TACE plus Lenvatinib

Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)

DRUG

DEB-TACE plus PD-1 inhibitor

Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Le-Qun Li, PhD · Guangxi Medical University Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229355 on ClinicalTrials.gov